Sun Pharmaceutical Industries saw its consolidated net profit decline by 20% in the first quarter, settling at Rs 2,278 crore. However, operational revenue rose by 10%, reaching Rs 13,786 crore. The company’s performance was bolstered by solid growth in the Indian market and rising global sales of innovative medicines, including the launch of LEQSELVI in the United States.
